Frontiers | Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors | Cell and Developmental Biology
The role of immunotherapy in treating solid cancers | Cancer World Archive
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy | SpringerLink
Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
Impact Story: Determining the Clinical Benefit of Treatment Beyond Progression with Immune Checkpoint Inhibitors | FDA
Mechanism of action of anti-PD-1, anti-PD-L1, and anti-CTLA4.... | Download Scientific Diagram
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations | Journal for ImmunoTherapy of Cancer
Mechanism of action of PD-1 and PD-L1 inhibitors. The programmed cell... | Download Scientific Diagram
PD-1 inhibitor| Investigational Compounds | InOncology
Frontiers | Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer | Oncology
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade: Cell
JCM | Free Full-Text | Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
New modalities of cancer treatment for NSCLC: focus on immunotherapy | CMAR
Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action | Immunotherapy
Frontiers | Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice | Immunology
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therap | DDDT
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy | Cancer Discovery
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives - ScienceDirect
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer - ScienceDirect
Scheme 1. Mechanism of action of anti PD-1 and anti PD-L1 antibodies.... | Download Scientific Diagram
Release the B7.1! Anti-PD-L1 breaks PD-L1's grip
Definition of immune checkpoint inhibitor - NCI Dictionary of Cancer Terms - National Cancer Institute
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms - Annals of Oncology
